601A anti-VEGF Ab is under clinical development by Sunshine Guojian Pharmaceutical Shanghai and currently in Phase II for Age Related Macular Degeneration. According to GlobalData, Phase II drugs for Age Related Macular Degeneration have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 601A anti-VEGF Ab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

601A anti-VEGF Ab overview

Monoclonal antibody (601a) is under development for the treatment of age-related macular degeneration, diabetic macular edema, macular edema and branch retinal vein occlusion. The therapeutic candidate is administered through intravitreal route. It is a class I monoclonal antibody targeting vascular endothelial growth factor (VEGF).

It was under development for diabetic retinopathy, retinal vein occlusion, non-small cell lung cancer and cervical cancer, choroidal neovascularization.

Sunshine Guojian Pharmaceutical Shanghai overview

Sunshine Guojian Pharmaceutical Shanghai (Sunshine Guojian Pharmaceutical), a subsidiary of 3SBio Inc, is a biopharmaceutical company. It develops antibodies and drugs. The company provides pilot-scale development, industrialization and commercialization of antibody drugs. Sunshine Guojian Pharmaceutical products comprise yisaipu, genipa and septim. Sunshine Guojian Pharmaceutical pipeline products comprise anti-HER2 monoclonal antibody, anti-CD20 chimeric monoclonal antibody, and human CTLA4-antibody fusion protein. The company technologies include animal cell culture technology, animal cell suspension culture technology, animal cell culture technology and antibody pharmaceutical formulation technology. It collaborates with local agents in the Middle East, the Commonwealth of Independent States, Latin America and Asian countries. Sunshine Guojian Pharmaceutical is headquartered in Shanghai, China.

For a complete picture of 601A anti-VEGF Ab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.